A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer

Abstract

ABSTRACTErlotinib is a standard second-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). However, its efficacy for those patients with epidermal growth factor receptor (EGFR) wild-type (WT) tumors is undecided. In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. We found PFS and OS were significantly improved by erlotinib plus nab-paclitaxel. The adverse events were also well tolerable.